2234. Outcomes by Age and Gender from a Global Phase 3 Study of Delafloxacin (DLX) in Community-Acquired Bacterial Pneumonia (CABP)

BACKGROUND: Delafloxacin (DLX) is a fluoroquinolone, approved in the United States for treatment of ABSSSI. DLX has no preclinical signals for QT prolongation and has no QT prolongation in a validated challenge study. Risk of QT prolongation is a consideration in antibiotic selection for elderly hos...

Descripción completa

Detalles Bibliográficos
Autores principales: Madej, Andrzej, Pullman, John, Popescu, Monica, Quintas, Megan, Lawrence, Laura, Li, Yang, Cammarata, Sue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810084/
http://dx.doi.org/10.1093/ofid/ofz360.1912

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810084/
http://dx.doi.org/10.1093/ofid/ofz360.1912

Ejemplares similares